CompanyTNYANasdaqSouth San Francisco, CA

Tenaya Therapeutics

Tenaya Therapeutics develops gene therapies and small molecule inhibitors for heart disease.

SEC EDGAR ClinicalTrials.gov tenayatherapeutics.com

SCHEDULE 13GAug 24Latest SEC filing

Aug 5Latest story

August 2026

Tenaya reports Q2 2026 results with new TN-201, TN-401 data and Alnylam upfront payment

Aug 5Quarterly updateTenaya Therapeutics

July 2026

Tenaya Therapeutics ends lease on decommissioned manufacturing site

Jul 2PartnershipTenaya Therapeutics

June 2026

Tenaya Therapeutics names Eric Hyllengren as new CFO effective July 13, 2026

Jun 29PeopleTenaya Therapeutics